We studied serum thrombopoietin (TPO) levels and circulating numbers of platelet during five courses of myelosuppressive post-remission chemotherapy in three patients with acute leukemia in complete remission. Serum TPO levels were measured by a newly developed and sensitive sandwich enzyme-linked immunosorbent assay. In all courses, serum TPO levels changed reciprocally with the platelet counts. When platelets were transfused into patients near the time of platelet nadir, the TPO levels dropped temporarily, while platelet counts temporarily increased. In addition, platelets obtained after transfusion in a thrombocytopenic patient showed lower binding to biotinylated TPO than donor platelets prior to the transfusion. The finding indicated that the TPO receptors were saturated with endogenous TPO of the patient with a high serum TPO level. These results suggest that the platelet mass directly regulates serum TPO levels by receptor-mediated absorption and is one of the major regulators of serum TPO levels in humans.
Introduction
Thrombopoietin (TPO), the ligand for c-mpl, has recently been isolated and cloned. [1] [2] [3] [4] [5] [6] It stimulates proliferation of megakaryocytic progenitors, induces megakaryocytic differentiation, and increases platelet production in vivo and in vitro, [1] [2] [3] [4] [5] 7 and is most likely the primary regulator of megakaryocytopoiesis and platelet production. However, the regulatory mechanism of platelet production by TPO is not clearly understood at present. As a physiologic regulator of platelet production, TPO levels are expected to vary inversely and proportionally to changes in the platelet mass. In fact, in experimental animals, it has been suggested that platelet mass directly played a role in regulation of circulating levels of TPO. Since recombinant TPO has now been introduced into clinics, and hopefully expected to increase platelet production in thrombocytopenic patients, it is of great interest to measure TPO levels according to the change of platelet count in humans.
In this study, we simultaneously measured both serum TPO levels and peripheral blood platelet counts after myelosuppressive chemotherapy in three patients with acute myeloid leukemia in complete remission using a new accurate and sensitive sandwich enzyme-linked immunosorbent assay (ELISA). 8 In addition, we studied the binding of biotinylated TPO by platelets in vitro.
Patients and methods

Patients
Three patients with acute myeloid leukemia in complete remission were investigated. ELISA for serum TPO and platelet count Chinese hamster ovary cell-derived purified rhTPO, mouse anti-rhTPO monoclonal antibodies (TN1) and biotinylated rabbit anti-rhTPO F(abЈ) 2 polyclonal antibodies were kindly provided by Kirin Brewery Co., Ltd (Maebashi, Japan). Serum TPO levels were measured by a sensitive ELISA as described elsewhere. 8 Briefly, microtiter wells were coated over night with 10 g/ml TN1 monoclonal antibodies. rhTPO standards, serum samples or blanks were added to the wells and reacted with the coated TN1 overnight. After washing, 500 ng/ml biotinylated anti-rhTPO F(abЈ) 2 antibody was added to each well followed by streptavidin-alkaline phosphatase conjugate. The color was developed using an amplification system (Gibco BRL, Grand Island, NY, USA). 9 Bound TPO was quantified colorimetrically. The absorbance of each sample was subtracted from that of the sample incubated with TN1. The value of the blank for the standard was subtracted from the average value of each standard or the high TPO serum sample. The sample concentration was calculated by regression analysis for the standard curve. The quantitative limit of this assay was 0.09 fmol/ml. The coefficients of intra-and inter-assay vari-ation were from 3.0% to 4.9% and from 5.9% to 6.1%, respectively. Platelet counts in the peripheral blood were counted with a SE-9000 Automated Blood Cell Counter (Sysmex, Kobe, Japan). Blood samples for serum TPO levels and platelet counts were taken on day 0 of chemotherapy and one to four times a week until the recovery of the platelet count to the baseline level or until the start of next chemotherapy.
Non-radioisotopic TPO binding assay of platelets
Binding capacity of TPO to platelets was examined using biotinylated TPO. Biotinylation of TPO was performed using the same method for erythropoietin as described in our previous reports. 10 Briefly, 800 g of lyophilized TPO was dissolved in 500 l of 0.1 m sodium acetate buffer, pH 5.5. A freshly prepared 500 l solution of 2 mm sodium periodate in the same sodium acetate buffer was added and incubated at 0°C for 1 h. Then glycerol was added to give a final concentration of 15 mm. After 5-min incubation at 0°C, the excess sodium periodate was removed using a Fast desalting column HR10/10 (Pharmacia, Uppsala, Sweden). Biotin-LC-hydrazide (PIERCE, Rockford, IL, USA) was added to a fraction containing TPO to give a final concentration of 5 mm, and incubated at room temperature for 2 h. The biotin-labeling was stopped by adding 0.01 m Tris-HCl buffer, pH 7.5. The unbound reagent was removed using a Fast desalting column HR10/10 equilibrated in PBS containing 0.02% Tween 20. The elute containing biotin-TPO was concentrated by a Centricon-10 concentrator (Amicon, Beverly, MA, USA), and refined using a Superdex 75 HR10/30 (Pharmacia). The biotin-TPO concentration was determined by ELISA. The biological activity of biotin-TPO was confirmed to be the same as unlabeled TPO by a MTS assay. 11 Platelets obtained from a single normal donor which were transfused into patient 1 and those obtained from patient 1 1 h after the platelet transfusion at the time of the nadir of platelet count as shown in Figure 1a (indicated with an arrow) were examined for TPO binding assay. Platelets from the latter were prepared from plateletrich plasma obtained from whole blood anticoagulated with ACD. The platelets were washed with washing buffer (NaCl 90 mmol/l, KCl 5 mmol/l, MgCl 2 3 mmol/l, Na 2 HPO 4 8 mmol/l, NaH 2 PO 4 17 mmol/l, Na acetate 23 mmol/l, Na 3 citrate 17 mmol/l, adenine 2 mmol/l, glucose 23.5 mmol/l, dextran 0.1% and maltose 28.8 mmol/l, pH 6.5) as described previously, 12 and then incubated with 50 ng/ml biotin-TPO or, as controls, with biotin-TPO plus a 1000-fold excess of unlabeled TPO in washing buffer containing 2% FCS and 0.05% NaN 3 (binding buffer) at 37°C for 1 h. After incubation, cells were washed three times with the binding buffer, and incubated with 2 g/ml of streptavidin-RED670 conjugate (SA-RED670; Gibco BRL) at room temperature for 1 h. Then the cells were washed three times, and resuspended in the binding buffer.
Quantitative fluorescence analysis was performed with FACScan flow cytometer (Becton Dickinson, Sunnyvale, CA, USA). List mode data were collected for 20 000 events in an electronic gate for platelets displaying specific light-scatter properties. The Kolmogorov-Smirnov test (K-S test) was used for the calculation of the D value using FACScan research soft ware. 13 Details of the calculation method were described previously. 10, 14, 15 In short, the D value is the maximum vertical displacement between two cumulative frequency distributions for the cyto-fluorograms of two samples, where the horizontal axis is fluorescence intensity and the vertical is a relative number of cells. We calculated the D value by comparing the cumulative frequency distribution of SA-RED670 fluorescence intensity of cells in the absence of unlabeled TPO (total binding) with that of cells in the presence of an excess amount of unlabeled TPO (non-specific binding). We were able to detect the increase of fluorescence intensity due to the specific binding of SA-RED670 to the complex of biotin-TPO and TPO receptor.
Results
Serum TPO levels and platelet counts
Serum TPO levels and platelet counts were simultaneously measured after informed consent in three patients during the three courses of consolidation chemotherapy in patient 1, the first course of maintenance/intensification chemotherapy in patient 2 and the first course of consolidation chemotherapy in patient 3, as described above. All patients exhibited a period of severe chemotherapy-induced thrombocytopenia, which eventually recovered in 2-6 weeks. As shown in Figure  1 , the pre-treatment platelet counts in patient 1 course I (a), course II (b) and course III (c), patient 2 (d) and patient 3 (e) were 153 × 10 9 , 155 × 10 9 , 140 × 10 9 , 173 × 10 9 and 376 × 10 9 /l, respectively, and then the platelet counts decreased over the next 2 weeks. The minimum counts of platelets in patient 1 course I, course II and course III, patient 2 and patient 3 were 12 × 10 9 , 9 × 10 9 , 26 × 10 9 , 8 × 10 9 and 3 × 10 9 /l, respectively, and these patients received platelet transfusion two to nine times during the nadir period in each course of chemotherapy. Then the platelet counts returned to normal levels over 2-6 weeks. The serum TPO levels were low at the start of chemotherapy, and 1.43, 6.45, 4.85, 0.91 and 0.83 fmol/ml in patient 1 course I, course II and course III, patient 2 and patient 3, respectively. Then the levels increased and peaked at the time of the nadir of platelet counts, and the maximum values in patient 1 course I, course II and course III, patient 2 and patient 3 were 16.32, 30.89, 21.42, 25.60 and 27.20 fmol/ml, respectively. TPO levels then decreased and returned to the baseline levels. The TPO levels were inversely correlated with the platelet counts as shown in Figure 1 . All five courses in the three patients showed similar patterns.
We also simultaneously measured serum TPO levels and platelet counts just before and 1 h after platelet transfusion at the time of the nadir of platelet counts. Patients received 10 units of platelets, and one unit of platelets implies platelets obtained from 200 ml blood from a single donor. As shown in Figure 1 , TPO levels apparently dropped 1 h after the platelet transfusion inversely with an increase of platelet counts in all six examined points (indicated with arrows in Figure 1) . The values of TPO levels and platelet counts just before and 1 h after platelet transfusion are summarized in Table 1 . The decreased values of TPO were 4.02 ± 2.25 fmol/ml (mean ± s.d.) and the increased counts of platelets were 28 ± 11 × 10 9 /l (mean ± s.d.).
Non-radioisotopic TPO binding assay of platelets
We further examined the binding ability of biotin-TPO by platelets which were transfused into patient 1. Platelets from a normal donor prior to the transfusion into patient 1 showed 
Table 1
Serum TPO levels and platelet counts just before and 1 h after platelet transfusion (10 units) The time of measurement of serum TPO levels and platelet counts is indicated with an arrow in Figure 1 .
Serum thrombopoietin levels and platelet counts K Shinjo et al 298 significantly increased florescence intensity due to the specific binding of biotin-TPO to TPO receptors (Figure 2a) , and the D value was 0.26. On the other hand, no detectable binding of biotin-TPO was observed in platelets obtained from patient 1 1 h after the platelet transfusion (Figure 2b) , and the D value was 0.02. These data indicated that exogenous TPO bound to platelets from a normal donor but not to platelets from a patient with severe thrombocytopenia and with a high endogenous serum TPO level.
Discussion
TPO is most likely the primary regulator of megakaryocytopoiesis and platelet production. However, the regulatory mechanism to maintain relatively constant platelet counts is not clearly understood at present. Recent studies on serum TPO and TPO mRNA in animals have suggested that serum TPO levels are regulated at a post-transcriptional level and/or directly through absorption and metabolism by platelet mass. [16] [17] [18] However, other observations indicate that TPO levels may be regulated principally by megakaryocyte mass 19 or by modulating TPO mRNA levels in response to platelet demand. 20 Because serum TPO levels are very low in humans and difficult to quantify, levels have generally been estimated indirectly by the bioassay of megakaryocyte stimulating activity 16 or by the proliferation assay of TPO-responsive cell lines. 17, 21 In these bioassays, non-specific stimulators or inhibitors in the blood samples may affect the estimation. Recently, Emmons et al 19 reported a receptor captured enzyme immunoassay for TPO in humans. However, the detection limit of the assay was 150-200 pg/ml, and was not enough to detect low levels of serum TPO such as those in normal individuals. More recently Tahara et al 8 new accurate and sensitive ELISA system for the measurement of TPO levels in the blood and other biological fluids. This ELISA does not cross-react with a variety of blood components and cytokines, producing no false-positive results. This assay is very sensitive and its quantitative limit is 0.09 fmol/ml which is below the serum levels of normal individuals. By this sensitive ELISA, we quantitatively measured the TPO levels in relation to the platelet counts in three patients with acute myeloid leukemia in CR who received myelosuppressive postremission chemotherapy.
In animal studies, serum TPO levels were high during thrombocytopenic phase and changed reciprocally to platelet mass over the entire time course after myelosuppressive therapy. 16 Also in human studies, TPO levels changed reciprocally to platelet counts in patients with cyclic thrombocytopenia or undergoing bone marrow transplantation after myeloablative therapy. [21] [22] [23] [24] On the other hand, it was described that TPO levels were high when thrombocytopenia was due to megakaryocyte deficiency, and low when due to increased platelet destruction, 19 and that serum megakaryocyte colony-stimulating activity levels appeared to be inversely related to marrow megakaryocyte numbers. 25 In the present study, we could clearly demonstrate using a sensitive ELISA that human TPO levels also changed inversely with the number of platelets after myelosuppressive chemotherapy. Furthermore, when platelets were transfused into patients at the time of nadir of platelet counts, elevated TPO levels dropped rapidly by around 4.0 fmol/ml within 1 h of the platelet transfusion, while platelet counts increased by around 28 × 10 9 /l. In a biotin-TPO binding experiment, the binding ability of platelets to TPO significantly decreased when they were transfused into a patient with a high serum TPO level. The data indicated that TPO receptors of the transfused platelets probably bound to serum TPO and were saturated with high circulating levels of TPO present in the thrombocyto-penic patient. These findings strongly suggest that the platelet mass directly regulates serum TPO levels by receptormediated absorption, and is plausibly a major regulator of serum TPO levels in humans as indicated by a mouse model. 18 Although the number of patients examined in this study was small, we believe that our data are representative because our sensitive ELISA is reliable and the results are consistent in all five courses in the three patients.
In a mouse model, TPO ameliorated carboplatin-induced thrombocytopenia. 26 In humans, the administration of recombinant human TPO to patients with advanced solid tumors increased the circulating platelet counts. [27] [28] [29] Thus, TPO will play an important clinical role for the platelet production in both natural and iatrogenic states of marrow failure. Further clinical trials of TPO will help to clarify the role of TPO in the regulatory mechanism of megakaryopoiesis in vivo.
